# Tamoxifen in the Prevention of Breast Cancer in Hodgkin's Disease Survivors

> **NCT00165308** · NA · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 29 (actual)

## Conditions studied

- Hodgkin's Disease
- Breast Cancer

## Interventions

- **DRUG:** Tamoxifen

## Key facts

- **NCT ID:** NCT00165308
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-04
- **Primary completion:** 2004-03
- **Final completion:** 2009-06
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2014-07-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00165308

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00165308, "Tamoxifen in the Prevention of Breast Cancer in Hodgkin's Disease Survivors". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00165308. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*